title: Fibroblast growth factor-2 induces recovery of pulmonary blood flow in canine emphysema models.
abstract: OBJECTIVE
  Fibroblast growth factor (FGF)-2 is one of the most powerful angiogenic growth factors to be evaluated as an agent for the promotion of angiogenesis. The aim of this study is to investigate whether intratracheal administration of controlled-release FGF-2 microspheres restores pulmonary function in beagle dogs with emphysema.
  
  
  METHODS
  Randomized, controlled, experimental animal study.
  
  
  METHODS
  Eighteen Wister rats and 15 adult beagle dogs.
  
  
  METHODS
  In the rat study, we compared the time profiles of the radioactivity remaining after intratracheal injection of 125I-labeled FGF-2, either incorporated with the controlled-release microspheres or as an aqueous solution. In the dog study, elastase-induced emphysema models were developed in 10 animals, classified into the following three groups: control group (n = 5), emphysema model with empty microspheres-treated group (FGF - group, n = 5), and emphysema model with FGF-2 containing microspheres-treated group (FGF + group, n = 5).
  
  
  RESULTS
  In the rat study, controlled-release microspheres maintained higher whole-lung FGF-2 concentrations after intratracheal administration. In the dog study, Pa(O2) in the FGF + group was significantly higher than in the FGF - group after treatment. Pulmonary perfusion dynamic MRI revealed significant improvement in the signal intensity of damaged lung with the FGF + group. Linear intercept of the FGF + group was significantly reduced than the FGF - group.
  
  
  CONCLUSIONS
  Results indicate that intratracheal administration of FGF-2 induced an increase in pulmonary blood flow in the damaged lung and led to recovery of pulmonary function. The controlled-release microsphere system increased the effectiveness of FGF-2.
authors.affiliation: Division of Surgical Oncology, Nagasaki University School of Medicine, Japan. morinos@frontier.kyoto-u.ac.jp
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Morino
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Nakamura
authors.forename: Toshinari
authors.initials: T
authors.lastname: Toba
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Takahashi
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kushibiki
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tabata
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Shimizu
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology* / Q000502:physiology / Q000627:therapeutic use; D011652:Pulmonary Circulation / Q000187:drug effects* / Q000502:physiology; D011656:Pulmonary Emphysema / Q000188:drug therapy / Q000503:physiopathology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D016222:Fibroblast Growth Factor 2